Merck Board Creates Committee To Review Vioxx Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Independent assessment is needed to "ensure that the company acted in an appropriate and ethical manner." The board also retains Debevoise & Plimpton attorney John Martin to assist in the review.
You may also be interested in...
Vioxx Withdrawal Is Not Affecting Access To Physicians, Merck Says
The Vioxx withdrawal is not having a spill-over effect on Merck's relationship with physicians, the company maintains
Vioxx Withdrawal Is Not Affecting Access To Physicians, Merck Says
The Vioxx withdrawal is not having a spill-over effect on Merck's relationship with physicians, the company maintains
FDA Has One Month To Mull Approval Of Merck's Arcoxia Following Vioxx Withdrawal
Arcoxia's user fee date is Oct. 30, but FDA could decide to wait for 18-month cardiovascular safety data from a 20,000-patient trial comparing etoricoxib with diclofenac. Merck says it will work with regulatory authorities in 47 countries where Arcoxia is marketed to discuss potential labeling changes resulting from the Vioxx study data.